Smoking-responsive juvenile-onset Parkinsonism

Movement Disorders

Volumn 22, Issue 1, 2007, Pages 115-119

  Hanagasi, Hasmet Ayhan ^a   Lees, Andrew ^b   Johnson, Janel O ^b,c   Singleton, Andrew ^c   Emre, Murat ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Juvenile onset Parkinsonism; Nicotine; Sensitivity

Indexed keywords

BIPERIDEN; BROMOCRIPTINE; LEVODOPA; NICOTINE; QUETIAPINE;

ADULT; ANAMNESIS; ARTICLE; CASE REPORT; CIGARETTE SMOKING; CLINICAL FEATURE; HUMAN; LOW DRUG DOSE; MALE; MEDICAL EXAMINATION; MOTOR PERFORMANCE; NEUROLOGIC EXAMINATION; OCULOGYRIC CRISIS; PARKINSONISM; PRIORITY JOURNAL; PSYCHOSIS; TREATMENT OUTCOME;

ADULT; HUMANS; MALE; NICOTINE; NICOTINIC AGONISTS; PARKINSONIAN DISORDERS; SMOKING; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TROPANES;

EID: 33847737313     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.21177     Document Type: Article

References (34)

1. Paviour DC, Surtees RA, Lees AJ. Diagnostic considerations in juvenile parkinsonism. Mov Disord 2004;19:123-135.
2. Fratiglioni L, Wang HX. Smoking and Parkinson's and Alzheimer's disease: review of the epidemiological studies. Behav Brain Res 2000;113:117-120.
3. Hernan MA, Takkouche B, Caamano-Isorna F, Gestal-Otero JJ. A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease. Ann Neurol 2002;52:276-284.
4. Maggio R, Riva M, Vaglini F, et al. Nicotine prevents experimental parkinsonism in rodents and induces striatal increase of neurotrophic factors. J Neurochem 1998;71:2439-2446.
5. Parain K, Hapdey C, Rousselet E, Marchand V, Dumery B, Hirsch EC. Cigarette smoke and nicotine protect dopaminergic neurons against the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Parkinsonian toxin. Brain Res 2003;984:224-232.
6. Levin ED, McGurk SR, Rose JE, Butcher LL. Cholinergic-dopaminergic interactions in cognitive performance. Behav Neural Biol 1990;54:271-299.
7. Pidoplichko VI, DeBiasi M, Williams JT, Dani JA. Nicotine activates and desensitizes midbrain dopamine neurons. Nature 1997;390:401-404.
8. Wonnacott S, Kaiser S, Mogg A, Soliakov L, Jones IW. Presynaptic nicotinic receptors modulating dopamine release in the rat striatum. Eur J Pharmacol 2000;393:51-58.
9. Moll H. The treatment of post-encephalitic parkinsonism by nicotine. Br Med J 1926;1:1079-1081.
10. Marshall J, Schnieden H. Effect of adrenaline, noradrenaline, atropine, and nicotine on some types of human tremor. J Neurol Neurosurg Psychiatry 1966;29:214-218.
11. Ishikawa A, Miyatake T. Effects of smoking in patients with early-onset Parkinson's disease. J Neurol Sci 1993;117:28-32.
12. Fagerstrom KO, Pomerleau O, Giordani B, Stelson F. Nicotine may relieve symptoms of Parkinson's disease. Psychopharmacology (Berl) 1994;116:117-119.
13. Lees AJ. Hemidystonia relieved by nicotine. Lancet 1984;8407:871.
14. Johnsen JA, Miller VT. Tobacco intolerance in multiple system atrophy. Neurology 1986;36:986-988.
15. Storch A, Ludolph AC, Schwarz J. Dopamine transporter: involvement in selective dopaminergic neurotoxicity and degeneration. J Neural Transm 2004;111:1267-1286.
16. Poewe W, Scherfler C. Role of dopamine transporter imaging in investigation of parkinsonian syndromes in routine clinical practice. Mov Disord 2003;18(Suppl. 7):S16-S21.
17. Gordon N. Dopa-responsive dystonia: a widening spectrum. Dev Med Child Neurol 1996;38:554-559.
18. Naumann M, Pirker W, Reiners K, et al. [123I]β -CIT single-photon emission computed tomography in DOPA-responsive dystonia. Mov Disord 1997;12:448-451.
19. Jeon BS, Jeong JM, Park SS, et al. Dopamine transporter density measured by [123I]beta-CIT single-photon emission computed tomography is normal in dopa-responsive dystonia. Ann Neurol 1998;43:792-800.
20. O'Sullivan JD, Costa DC, Gacinovic S, Lees AJ. SPECT imaging of the dopamine transporter in juvenile-onset dystonia. Neurology 2001;56:266-267.
21. Ebersbach G, Stock M, Muller J, Wenning G, Wissel J, Poewe W. Worsening of motor performance in patients with Parkinson's disease following transdermal nicotine administration. Mov Disord 1999;14:1011-1013.
22. Kelton MC, Kahn HJ, Conrath CL, Newhouse PA. The effects of nicotine on Parkinson's disease. Brain Cogn 2000;43:274-282.
23. Vieregge A, Sieberer M, Jacobs H, Hagenah JM, Vieregge P. Transdermal nicotine in PD: a randomized, double-blind, placebo-controlled study. Neurology 2001;57:1032-1035.
24. Lemay S, Chouinard S, Blanchet P, et al. Lack of efficacy of a nicotine transdermal treatment on motor and cognitive deficits in Parkinson's disease. Prog Neuropsychopharmacol Biol Psychiatry 2004;28:31-39.
25. Dogu O, Crawley A, Werner K, Gwinn-Hardy K, Lopez G. A subject with a homozygous exon 4 parkin deletion whose parkinsonism dramatically improves following smoking. Mov Disord 2004;19(Suppl. 9):359.
26. Quik M, Kulak JM. Nicotine and nicotinic receptors; relevance to Parkinson's disease. Neurotoxicology 2002;23:581-594.
27. Jones GM, Sahakian BJ, Levy R, Warburton DM, Gray JA. Effects of acute subcutaneous nicotine on attention, information processing and short-term memory in Alzheimer's disease. Psychopharmacology (Berl) 1992;108:485-494.
28. Levin ED. Nicotinic systems and cognitive function. Psychopharmacology (Berl) 1992;108:417-431.
29. Newhouse PA, Potter A, Singh A. Effects of nicotinic stimulation on cognitive performance. Curr Opin Pharmacol 2004;4:36-46.
30. Perry EK, Smith CJ, Court JA, Perry RH. Cholinergic nicotinic and muscarinic receptors in dementia of Alzheimer, Parkinson and Lewy body types. J Neural Transm Park Dis Dement Sect 1990;2:149-158.
31. Lange KW, Wells FR, Rossor MN, Jenner P, Marsden CD. Cortical nicotinic receptors in Alzheimer disease and Parkinson's disease. J Neurol Neurosurg Psychiatry 1991;54:373-374.
32. Rinne JO, Myllykylä T, Lönnberg P, Marjamäki P. A postmortem study of brain nicotinic receptors in Parkinson's and Alzheimer's disease. Brain Res 1991;547:167-170.
33. Aubert I, Araujo DM, Cecyre D, Robitaille Y, Gauthier S, Quirion R. Comparative alterations of nicotinic and muscarinic binding sites in Alzheimer's and Parkinson's diseases. J Neurochem 1992;58:529-541.
34. Perry EK, Morris CM, Court JA, et al. Alteration in nicotine binding sites in Parkinson's disease, Lewy body dementia and Alzheimer's disease: possible index of early neuropathology. Neuroscience 1995;64:385-395.